Detalhe da pesquisa
1.
Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity.
Nature;
570(7761): E53, 2019 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31142845
2.
Design of amidobenzimidazole STING receptor agonists with systemic activity.
Nature;
564(7736): 439-443, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30405246
3.
The discovery and structure-activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase.
Bioorg Med Chem Lett;
20(9): 2968-73, 2010 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20347591
4.
Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.
Bioorg Med Chem Lett;
20(1): 387-91, 2010 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19919895
5.
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.
ACS Med Chem Lett;
10(6): 857-862, 2019 Jun 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31223438
6.
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.
J Med Chem;
62(10): 5096-5110, 2019 05 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31013427
7.
Discovery of a series of aminopiperidines as novel iNOS inhibitors.
Bioorg Med Chem Lett;
18(1): 336-43, 2008 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18024030
8.
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.
J Med Chem;
60(4): 1247-1261, 2017 02 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28151659
9.
Medicinal chemistry strategies to reduce CYP2D6 inhibitory activity of lead candidates.
Curr Med Chem;
16(24): 3093-121, 2009.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19689286
10.
Design and Synthesis of Imidazopyrimidine Derivatives as Potent iNOS Dimerization Inhibitors.
Open Med Chem J;
3: 8-13, 2009 Nov 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19966921
11.
Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).
J Med Chem;
52(18): 5685-702, 2009 Sep 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19694468
12.
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
J Med Chem;
51(19): 5893-6, 2008 Oct 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18788723